Colchicine
- Generic Name
- Colchicine
- Brand Names
- Colcrys, Gloperba, Lodoco, Mitigare
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25NO6
- CAS Number
- 64-86-8
- Unique Ingredient Identifier
- SML2Y3J35T
- Background
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammato...
- Indication
Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established ather...
- Associated Conditions
- Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke
- Associated Therapies
- -
Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Maria Joyera Rodríguez
- Target Recruit Count
- 54
- Registration Number
- NCT04492358
- Locations
- 🇪🇸
Hospital Clinic, Department of Internal Medicine, Barcelona, Spain
🇪🇸Clinica Sant Antoni, Barcelona, Spain
🇪🇸Centre Blauclínic Dolors Aleu, Barcelona, Spain
COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 54
- Registration Number
- NCT04420624
- Locations
- 🇫🇷
UH Montpellier, Montpellier, France
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-11-25
- Target Recruit Count
- 70
- Registration Number
- NCT04403243
- Locations
- 🇷🇺
Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation
Oral Colchicine in Argentina to Prevent Restenosis
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-03-18
- Target Recruit Count
- 450
- Registration Number
- NCT04382443
- Locations
- 🇦🇷
Sanatorio Otamendi, Ciudad de Buenos Aires, Buenos Aires, Argentina
🇦🇷Sanatorio Las Lomas, San Isidro, Buenos Aires, Argentina
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Colchicine in Patients With Mild and Severe Coronavirus Disease
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2022-08-10
- Target Recruit Count
- 116
- Registration Number
- NCT04367168
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Maimonides Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT04363437
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Estudios Clínicos Latino América
- Target Recruit Count
- 1279
- Registration Number
- NCT04328480
- Locations
- 🇦🇷
Sanatorio Parque, Rosario, Santa Fe, Argentina
The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- National and Kapodistrian University of Athens
- Target Recruit Count
- 105
- Registration Number
- NCT04326790
- Locations
- 🇬🇷
National and Kapodistrian University of Athens, Athens, Greece
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
- Conditions
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 6667
- Registration Number
- NCT04324463
- Locations
- 🇨🇦
Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada
🇧🇷Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil
🇨🇦London Health Sciences Centre, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.